Anchiano Therapeutics Ltd - Financial and Strategic SWOT Analysis Review

May 2020 | 44 pages | ID: A0810C2168BEN
GlobalData

Abstracts

Anchiano Therapeutics Ltd - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Anchiano Therapeutics Ltd (Anchiano) formerly BioCancell Ltd, is a preclinical stage biopharmaceutical company that focuses on the discovery, development and commercialization of therapies for the diagnosis and treatment of cancer. Its pipeline drug candidates find application inhibition of Oncogenic and germline mutations for the treatment of ovarian cancer and pancreatic cancer. The company researches on its proprietary, personalized cancer therapy approach Human gene H19, which plays a key role in the development, progress, drug resistance and metastasis of most human cancers. Anchiano is headquartered in Cambridge, Massachusetts, the US.

Anchiano Therapeutics Ltd Key Recent Developments

May 26,2020: Anchiano appoints Stan Polovets as Chairman of the Board
May 11,2020: Anchiano Therapeutics reports first quarter 2020 financial results
May 05,2020: Anchiano appoints Steve DiPalma as Chief Financial Officer
Mar 18,2020: Anchiano Therapeutics reports year-end 2019 financial results
Nov 15,2019: Anchiano Therapeutics reports third quarter 2019 financial results and provides corporate update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Anchiano Therapeutics Ltd - Key Facts
Anchiano Therapeutics Ltd - Key Employees
Anchiano Therapeutics Ltd - Key Employee Biographies
Anchiano Therapeutics Ltd - Major Products and Services
Anchiano Therapeutics Ltd - History
Anchiano Therapeutics Ltd - Company Statement
Anchiano Therapeutics Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Anchiano Therapeutics Ltd - Business Description
Anchiano Therapeutics Ltd - SWOT Analysis
SWOT Analysis - Overview
Anchiano Therapeutics Ltd - Strengths
Anchiano Therapeutics Ltd - Weaknesses
Anchiano Therapeutics Ltd - Opportunities
Anchiano Therapeutics Ltd - Threats
Anchiano Therapeutics Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Anchiano Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Anchiano Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Anchiano Therapeutics Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 26, 2020: Anchiano appoints Stan Polovets as Chairman of the Board
May 11, 2020: Anchiano Therapeutics reports first quarter 2020 financial results
May 05, 2020: Anchiano appoints Steve DiPalma as Chief Financial Officer
Mar 18, 2020: Anchiano Therapeutics reports year-end 2019 financial results
Nov 15, 2019: Anchiano Therapeutics reports third quarter 2019 financial results and provides corporate update
Oct 24, 2019: Anchiano Therapeutics Chairman Stephen Hoffman steps down from Board
Aug 05, 2019: Anchiano Therapeutics reports second quarter 2019 financial results
May 29, 2019: Anchiano Therapeutics announces appointment of Salar Roshan as Head of Business Development
Mar 14, 2019: Anchiano Therapeutics initiates process to voluntarily delist its ordinary shares from the Tel Aviv Stock Exchange
Mar 12, 2019: Anchiano Therapeutics announces fourth quarter and full year 2018 financial results

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Anchiano Therapeutics Ltd, Key Facts
Anchiano Therapeutics Ltd, Key Employees
Anchiano Therapeutics Ltd, Key Employee Biographies
Anchiano Therapeutics Ltd, Major Products and Services
Anchiano Therapeutics Ltd, History
Anchiano Therapeutics Ltd, Subsidiaries
Anchiano Therapeutics Ltd, Key Competitors
Anchiano Therapeutics Ltd, Ratios based on current share price
Anchiano Therapeutics Ltd, Annual Ratios
Anchiano Therapeutics Ltd, Interim Ratios
Anchiano Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Anchiano Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Anchiano Therapeutics Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Anchiano Therapeutics Ltd, Performance Chart (2014 - 2018)
Anchiano Therapeutics Ltd, Ratio Charts
Anchiano Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Anchiano Therapeutics Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Viralytics Pty Ltd
Telesta Therapeutics Inc
Taris Biomedical LLC
Sesen Bio Inc
Nippon Kayaku Co Ltd
Merck Sharp & Dohme Corp
Heat Biologics Inc
Halozyme Therapeutics Inc
Astellas Pharma Inc
Aadi LLC